]>
IRCT20191012045075N1 IRCT 2020-01-26 Zahedan University of Medical Sciences Comparison of intravenous enoxaparin with subcutaneous enoxaparin in preventing venous thromboembolism Comparison of intravenous enoxaparin with subcutaneous enoxaparin in preventing venous thromboembolism in patients admitted to intensive care unit 2013-09-23 anticipated 20 Complete https://irct.ir/trial/43023 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients were selected by the convenience sampling method based on inclusion criteria, and then randomly divided into two groups. To ensure the randomization process, a total of 20 green and orange cards (corresponding to the estimated sample size) were prepared. A total of 10 green and 10 orange cards were assigned to each group, respectively the cards were arranged in the black box. After the patient having the inclusion criteria. A card was picked up from the box. And if the card was green, the patients assigned to the group I (subcutaneous enoxaparin). And if it was orange the patients assigned to group II(intravenous enoxaparin), Blinding description: Laboratory personnel who measured the patient's blood factor levels were unaware of the patients' placement in the study groups. N/A Intravenous thromboembolism. Intervention 1: In the first group, 0.5 mg/kg of enoxaparin (AVENTIS PHARMA Co., France) was injected subcutaneously in the deltoid region and rotationally the internal surface of the groin on both sides of the body. Intervention 2: In the second group, 0.5 mg/kg of enoxaparin (AVENTIS PHARMA Co., France) was injected slowly through a peripheral vein. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information
public Masoum khoshfetrat
Zahedan, Jame jam ave, khatam alanbia hospital
Zahedan Iran (Islamic Republic of) 9861715799 +98 915 349 0213 khoshfetrat@zaums.ac.ir Zahedan University of Medical Sciences scientific Masoum Khoshfetrat
Jame jam Ave,
Zahedan Iran (Islamic Republic of) 9815733169 +98 54 3322 0501 drkhoshfetrat@yahoo.com Zahedan University of Medical Sciences Iran (Islamic Republic of) Ages 18 to 70 years Hospitalization for at least 48 hours in ICU Mechanical ventilation Normal renal and hepatic function Passing 48 hours from surgery in patients with intracerebral hemorrhage (epidural , subdural and intracerebral hematoma and hemorrhagic stroke) 18 years 70 years Both History of deep vein thrombosis History of pulmonary embolism History of coagulation disorders (hemophilia, disseminated intravascular coagulation, idiopathic thrombocytopenia, heparin- induced thrombocytopenia and disruption of coagulation tests) Treated with other anticoagulants before hospitalization Prosthetic implantation (artificial heart valve, stent and IVC filter) Myelodysplastic syndrome and other blood dyscrasias Treatment - Drugs Treatment - Drugs In the first group, 0.5 mg/kg of enoxaparin (AVENTIS PHARMA Co., France) was injected subcutaneously in the deltoid region and rotationally the internal surface of the groin on both sides of the body. In the second group, 0.5 mg/kg of enoxaparin (AVENTIS PHARMA Co., France) was injected slowly through a peripheral vein. Active factor Xa level. Timepoint: At baseline, 4 hours after the first injection, day 10 of the study 12 hours after the last injection. Method of measurement: The measurement of active factor levels was followed up by the laboratory without the researchers' knowledge of how the test was performed. Zahedan University of Medical Sciences Approved 2013-07-28 Ethics committee of Zahedan University of Medical Sciences Campus of Medical Sciences, Dr. Hassabi Square., University Ave., Zahedan Town zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)